Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05387551
Other study ID # lfox051622
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2022
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Nemours Children's Clinic
Contact Larry Fox, MD
Phone 9046973674
Email larry.fox@nemours.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.


Description:

The purpose of this research is to evaluate if having blood sugar information from a continuous glucose monitor (CGM) during activities of daily living provides additional benefit to lifestyle modifications in reducing the risk of developing diabetes and achieving a healthier weight. A CGM is a small device often worn on the back of the arm that uses a very small needle to insert a small sensor just under the skin in the fatty tissue. The CGM device transmits the blood sugar level to either a smartphone or a special receiver. The investigators expect patients will have an overall improvement in health by decreasing weight and therefore improving the way the child's insulin works in their body. This could result in decreased risk of obesity-related complications such as diabetes mellitus, cardiovascular disease, kidney disease, and loss of vision and/or limbs, among others.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 16 Years
Eligibility Inclusion Criteria: 1. Children 10 to <17 years old (i.e., before their 17th birthday) 2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) or fasting glucose per American Diabetes Association criteria, 3. Overweight or obese (BMI =85th percentile for age/sex) 4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume =4 mL Exclusion Criteria: 1. Existing diagnosis of type 1 or type 2 diabetes 2. Prepubertal 3. Taking medications that affect insulin sensitivity (e.g.,chronic corticosteroids whether systemic or inhaled). Metformin allowed if stable dose. 4. Patients and/or families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CGM
Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.

Locations

Country Name City State
United States Nemours Children's Clinic Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Nemours Children's Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Insulin Sensitivity Score (ISS) Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance. Baseline to 6 months
Secondary QUICKI insulin sensitivity Change in insulin sensitivity as measured by QUICKI Baseline to 3 months
Secondary QUICKI insulin sensitivity Change in insulin sensitivity as measured by QUICKI Baseline to 6 months
Secondary Insulin Sensitivity Score Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance. Baseline to 3 months
Secondary Glycemic levels Change in characteristics of glycemic levels obtained from the CGM data. This will include:
mean, standard deviation of glucose levels
time in range (glucose between 70-140 mg/dL)
percent of time with hyperglycemia (>140 mg/dL)
percent of time with hypoglycemia (<70 mg/dL)
Baseline to 3 and 6 months
Secondary Mean, standard deviation of sensor glucose levels Change in characteristics of glycemic levels obtained from the CGM data, including mean and standard deviation of sensor glucose levels (mg/dL). Baseline to 3 and 6 months
Secondary Time in range of sensor glucose levels Change in glycemic levels obtained from the CGM data: Percent of time in range (glucose between 70-140 mg/dL) Baseline to 3 and 6 months
Secondary Percent of sensor glucose levels in hypoglycemic range Change in glycemic levels obtained from the CGM data: Percent of time with hypoglycemia (<70 mg/dL) Baseline to 3 and 6 months
Secondary Percent of sensor glucose levels in hyperglycemic range Change in glycemic levels obtained from the CGM data: Percent of time with hyperglycemia (>140 mg/dL) Baseline to 3 and 6 months
Secondary Physical activity questionnaires Questionnaires will be used to assess amount of time participants are active. Two questions regarding physical activity will be asked, with a scale set up as follows:
How many minutes of continuous physical activity per week were completed? Possible answers will be <10, 11-20, 21-30, 31-60, 61-90, 91-120, or 121-150.
How many days per week of physical activity longer than 30 minutes? Possible answers will be 0, 1, 2, 3, 4, 5, 6, or 7.
3 and 6 months
Secondary Dietary compliance questionnaires Questionnaires will be used to assess particpants' compliance witih dietary changes. Four questions regarding their diet will be asked, with a scale set up as follows:
How many sugary drinks per week? Possible answers will be 0, 1-2, 3-5, or >5.
How many unhealthy snacks per week? Possible answers will be 0, 1-2, 3-5, or >5.
How many times junk food was consume in the past week? Possible answers will be 0, 1-2, 3-5, or >5.
How often were the proper portion sizes followed (as per control plate)? Possible answers will be always, most days, occasionally, or never.
3 and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Completed NCT02621060 - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance Phase 2
Completed NCT01521312 - ACute and Chronic Effects of Saxagliptin Phase 2
Completed NCT01488279 - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy N/A
Completed NCT01559896 - Egg Protein Hydrolysate and Vascular Function N/A
Completed NCT01030978 - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program N/A
Completed NCT00573781 - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism Phase 2
Terminated NCT00846521 - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity Phase 4
Completed NCT00241072 - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Phase 4
Completed NCT00536250 - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth N/A
Completed NCT02254317 - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance N/A
Completed NCT03764423 - Health Effects of Salmon Fishmeal in Humans N/A
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Active, not recruiting NCT04341571 - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes. Phase 2
Completed NCT02700334 - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Phase 4
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Completed NCT02135172 - Breaks in Sedentary Time and Glucose Regulation in Women N/A
Active, not recruiting NCT01841229 - Effect of Ginseng on Glycemic Control N/A
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A